What is Nebu~Flow?
Nebu-Flow operates at the intersection of advanced engineering and respiratory medicine. The company specializes in the development of next-generation nebulisers designed to facilitate the precise inhalation delivery of life-changing treatments. By utilizing patented aerosol formation technology, Nebu-Flow enables the efficient administration of drugs that have historically proven difficult to nebulise. The organization is composed of a multidisciplinary team of technologists and respiratory experts dedicated to refining drug delivery mechanisms. Through strategic collaborations within the healthcare sector, Nebu-Flow aims to redefine the standard of care for patients suffering from chronic respiratory conditions, positioning itself as a key innovator in the medical device market.
How much funding has Nebu~Flow raised?
Nebu~Flow has raised a total of $9.1M across 3 funding rounds:
Unspecified
$2M
Grant
$1.2M
Other Financing Round
$5.9M
Unspecified (2022): $2M with participation from Foresight Williams Technology
Grant (2022): $1.2M led by Innovate UK
Other Financing Round (2024): $5.9M supported by Scvc and WAE Technologies
Key Investors in Nebu~Flow
Innovate UK
Innovate UK is the national innovation agency of the UK, dedicated to supporting business-led innovation across various sectors and technologies to foster economic growth.
Scvc
An association focused on collaborative educational frameworks and community-based support systems, providing strategic oversight and network connections.
WAE Technologies
A world-leading technology and engineering firm originating from the high-performance environment of Williams F1, specializing in advanced technical solutions.
What's next for Nebu~Flow?
Looking ahead, the infusion of capital will be directed toward scaling the company's manufacturing capabilities and expanding its clinical validation programs. The strategic focus will remain on forging partnerships with pharmaceutical entities to integrate Nebu-Flow's technology into existing drug pipelines. As the company matures, the emphasis will shift toward regulatory milestones and market entry, ensuring that their innovative nebulisation solutions reach clinical settings efficiently. This growth phase is critical for establishing Nebu-Flow as a leader in respiratory technology, with the current funding providing the necessary runway to achieve long-term commercial viability and technological dominance in the field of aerosolized drug delivery.
See full Nebu~Flow company page
